Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | JUN | P05412 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565762 | 0.90 | ALDH1A1 (0.49) | ALDH1A1MAPTRAB9ANPSR1KCNH2 | |
| SCHEMBL2566454 | 0.90 | ALDH1A1 (0.51) | ALDH1A1MAPTRAB9ANPSR1KCNH2 | |
| SCHEMBL2562815 | 0.90 | ALDH1A1 (0.51) | ALDH1A1MAPTRAB9ANPSR1KCNH2 | |
| SCHEMBL2561941 | 0.90 | ALDH1A1 (0.51) | ALDH1A1MAPTRAB9ANPSR1KCNH2 | |
| SCHEMBL2564148 | 0.90 | ALDH1A1 (0.51) | ALDH1A1MAPTRAB9ANPSR1KCNH2 | |
| SCHEMBL15512657 | 0.89 | MAPK1 (0.57) | SMN1; SMN2ALDH1A1MAPTRAB9ANPSR1 | |
| SCHEMBL2567691 | 0.88 | ALDH1A1 (0.49) | ALDH1A1MAPTRAB9ANPSR1KCNH2 | |
| SCHEMBL2562510 | 0.88 | ALDH1A1 (0.49) | ALDH1A1MAPTRAB9ANPSR1KCNH2 | |
| SCHEMBL2562976 | 0.88 | ALDH1A1 (0.49) | ALDH1A1MAPTRAB9ANPSR1KCNH2 | |
| SCHEMBL2567963 | 0.88 | MAPT (0.56) | SMN1; SMN2ALDH1A1JUNMAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952021-B2 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2015-02-10 | — | — | US | claimed |
| EP-2382194-B1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP (CA) | 2014-03-12 | — | — | EP | claimed |
| US-20110294807-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2011-12-01 | — | — | US | claimed |
| EP-2382194-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2011-11-02 | — | — | EP | claimed |
| WO-2010079431-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2010-07-15 | — | — | WO | claimed |
| WO-2015081280-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015081284-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| EP-2660238-B1 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP (CA) | 2015-05-06 | — | — | EP | disclosed |
| EP-2660238-B1 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP (CA) | 2015-05-06 | — | — | EP | disclosed |
| US-8952021-B2 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-8952021-B2 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-8952021-B2 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2015-02-10 | — | — | US | disclosed |
| WO-2013033270-A2 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033269-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20110294807-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2011-12-01 | — | — | US | disclosed |
| US-20110294807-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2011-12-01 | — | — | US | disclosed |
| US-20110294807-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2011-12-01 | — | — | US | disclosed |
| EP-2382194-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010079431-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079431-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294807-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | APOB, APOL1, LDLR | SMN1; SMN2 3960/4885ALDH1A1 355/4885JUN 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.